Skip to main content
. Author manuscript; available in PMC: 2010 Jan 29.
Published in final edited form as: J Invest Dermatol. 2009 Apr 2;129(9):2156. doi: 10.1038/jid.2009.61

Figure 2. Binding capacity of anti-desmoglein 1 (Dsg1) single-chain variable fragment (scFv) mAbs to the Dsg1 ELISA plate changes after furin treatment.

Figure 2

(a) Baculovirally produced recombinant Dsg1 (Dsg1-EHis), visualized by immunoblot using anti-E-tag antibody. Dsg1-EHis was detected as double bands, which were considered to be precursor and mature form of Dsg1-EHis (left lane). After treatment with furin protease, only single band was observed (right lane). White arrowhead indicates the precursor form and black arrowhead indicates the mature form. (b) Comparison of anti-Dsg1 scFv mAbs bindings between furin-treated and Tris-buffered saline-calcium (TBS-Ca)-treated (control) Dsg1 ELISA plates. The ratio was calculated according to the following formula: (optical density (OD) values obtained in furin-treated wells)/(OD values obtained in TBS-Ca-treated wells). Control ratio (ratio = 1) is shown by a broken line. The binding of 3–30/3h, a pathogenic mAb, was significantly increased to nearly twofold, whereas that of 3–97/1c, non-pathogenic mAb was decreased. The binding of 1–18/L12 showed no significant change. AM3–13 is an irrelevant scFv and used as a control.